CDER Medical Policy Council Balances “Breakthrough” Requests With Broader Issues
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA is seeking public input on cross-cutting policy issues to bring before the senior-level group, which is also facing the challenge of reviewing dozens of “breakthrough therapy” designation requests relevant to CDER-regulated products.
You may also be interested in...
FDA's Combo Products Review Transformation Begins
Pilot project sets timelines for lead and consulting centers that will feed into more substantial changes in PDUFA VI.
Senior CDER Management Panel Could Facilitate Novel Therapy Approval
CDER Director Janet Woodcock is creating an executive-level forum to deliberate medical policies, including those needed to smooth drug reviews. She envisions stakeholder input on topics for discussion by the panel.
Antisense Oligonucleotide Clinical Guidance Emphasizes Individualized Nature Of Treatment
US FDA’ s latest ‘n of 1’ guidance describes clinical considerations for INDs to support dosing and monitoring of an individual with a life-threatening genetic disease who is eligible to receive an ASO; recommendations apply only when a few patients may be candidates for treatment.